ASV offers significant clinical benefits*

Compared to other forms of PAP therapy, ASV offers significant benefits for the treatment of central SDB*– including improvement of apnoea hypopnoea index (AHI), reduction of respiratory events and alleviation of daytime sleepiness. This has been demonstrated in multiple clinical trials across various patient types.

ASV better than CPAP at controlling respiratory events in patients with CompSA

In an intention-to-treat analysis, success (apnoeahypopnoea index [AHI] < 10) at 90 days of therapy was achieved in 89.7% of patients treated with ASV versus 64.5% of participants treated with CPAP.1

[N =66, prospective randomised trial]

 

ASV decreases residual sleepiness after APAP therapy in patients with mixed sleep apnoea

After 30 days of APAP treatment, ASV provided a further reduction (compared to baseline) of 12.9% in AHI, 48.5% in central sleep apnoea index (CSAI), 26.1% in micro-arousal index (MAI), and 37.9% in Epworth Sleepiness Scale (ESS) score at similar mean pressure.2

[N = 42, sequential study].

 

ASV better than bi-level ST at reducing respiratory events in opioid-induced CSA

In opioid-induced CSA, ASV therapy reduced AHI by 84.7%, central apnoea index (CAI) by 95.7%, apnoea index (AI) by 96.4%, and respiratory arousal index (RAI) by 77.1% when compared to bi-level ST. Respiratory parameters were normalised in 83.3% of patients on ASVAuto but only 33.3% of patientson bi-level ST.3

[N = 18, prospective, randomised crossover polysomnography study]

 

ASV improves AHI and ESS in post-acute ischemic stroke patients

ASV therapy improved outcomes for post-acute ischemic stroke patients with CSA, reducing AHI by 81.8% and ESS by 35.6%.4

[N = 15, single centre retrospective analysis]

 

ASV improves cardiac output and prognosis in Heart Failure with preserved Ejection Fraction*

Prospective randomised and observational heart failure studies (already presented and shortly to be published) have suggested that ASV may be beneficial in HF patients with preserved ejection fraction and in those who have CSA with coexisting obstructive sleep apnoea (OSA).5,6 Currently there is no evidence that these patients would be at any risk of harm from ASV therapy.

References

* ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.

  • 01

    Morgenthaler et al. The Complex Sleep Apnea Resolution Study, Sleep, Vol. 37, No. 5, 2014.

  • 02

    Su et al. Adaptive pressure support servoventilation: a novel treatment for residual sleepiness associated with central sleep apnea events, Sleep Breath, 2011;15:695-699.

  • 03

    Cao et al. A Novel Adaptive Servoventilation (ASVAuto) for the Treatment of Central Sleep Apnea Associated with Chronic Use of Opioids, Journal of Clinical Sleep Medicine, Vol. 10, No. 8, 2014.

  • 04

    Brill et al. Adaptive servo-ventilation as treatment of persistent central sleep apnea in post-acute ischemic stroke patients, Sleep Medicine 15, 2014;1309-1313.

  • 05

    Bitter T et al. Eur Respir J 2010; 36: 385–392

  • 06

    Yoshihisa et al. European Journal of Heart Failure doi:10.1093/eurjhf/hfs197